###begin article-title 0
Interactions between Cells with Distinct Mutations in c-MYC and Pten in Prostate Cancer
###end article-title 0
###begin p 1
Conceived and designed the experiments: SAA. Performed the experiments: JK MR. Analyzed the data: JK IEAE MR SAA. Contributed reagents/materials/analysis tools: JW SAA. Wrote the paper: JK SAA.
###end p 1
###begin p 2
###xml 506 510 506 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 807 811 807 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 860 871 860 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-MYC+;Pten</italic>
###xml 949 953 949 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1157 1161 1157 1161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1312 1316 1312 1316 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cip1</sup>
###xml 1309 1316 1309 1316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p21<sup>Cip1</sup></italic>
###xml 1360 1364 1360 1364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 3 8 <span type="species:ncbi:9606">human</span>
###xml 318 323 <span type="species:ncbi:10090">mouse</span>
###xml 763 767 <span type="species:ncbi:10090">mice</span>
In human somatic tumorigenesis, mutations are thought to arise sporadically in individual cells surrounded by unaffected cells. This contrasts with most current transgenic models where mutations are induced synchronously in entire cell populations. Here we have modeled sporadic oncogene activation using a transgenic mouse in which c-MYC is focally activated in prostate luminal epithelial cells. Focal c-MYC expression resulted in mild pathology, but prostate-specific deletion of a single allele of the Pten tumor suppressor gene cooperated with c-MYC to induce high grade prostatic intraepithelial neoplasia (HGPIN)/cancer lesions. These lesions were in all cases associated with loss of Pten protein expression from the wild type allele. In the prostates of mice with concurrent homozygous deletion of Pten and focal c-MYC activation, double mutant (i.e. c-MYC+;Pten-null) cells were of higher grade and proliferated faster than single mutant (Pten-null) cells within the same glands. Consequently, double mutant cells outcompeted single mutant cells despite the presence of increased rates of apoptosis in the former. The p53 pathway was activated in Pten-deficient prostate cells and tissues, but c-MYC expression shifted the p53 response from senescence to apoptosis by repressing the p53 target gene p21Cip1. We conclude that c-MYC overexpression and Pten deficiency cooperate to promote prostate tumorigenesis, but a p53-dependent apoptotic response may present a barrier to further progression. Our results highlight the utility of inducing mutations focally to model the competitive interactions between cell populations with distinct genetic alterations during tumorigenesis.
###end p 2
###begin title 3
Author Summary
###end title 3
###begin p 4
###xml 404 411 404 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 996 1000 996 1000 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1035 1040 1035 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-MYC</italic>
###xml 1042 1046 1042 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1083 1087 1083 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1144 1149 1144 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-MYC</italic>
###xml 1151 1155 1151 1155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1178 1182 1178 1182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 8 13 <span type="species:ncbi:9606">human</span>
###xml 474 489 <span type="species:ncbi:10090">transgenic mice</span>
###xml 591 595 <span type="species:ncbi:10090">mice</span>
###xml 1303 1308 <span type="species:ncbi:9606">human</span>
In most human cancers, mutations are thought to arise in a single cell or few cells surrounded by their unaffected neighbors. Expansion of mutant cells can then allow the accumulation of additional mutations. The cell-cell interactions that may occur between mutant and unaffected cells or between cells with distinct mutations during tumorigenesis have not been well studied due to the lack of suitable in vivo models. To help fill this gap, we generated and characterized transgenic mice in which the oncogene c-MYC is activated focally in prostate epithelial cells. We have also analyzed mice in which prostate epithelial cells with two mutations (c-MYC overexpression and loss of Pten tumor suppressor) are found next to cells with a single mutation (loss of Pten). Although loss of Pten in the prostate is tumorigenic, it also activates a cellular senescence response which restrains further tumor progression. We found that concurrent c-MYC expression suppressed the senescence response in Pten-null cells in favor of apoptosis. c-MYC+;Pten-null cells proliferated faster than Pten-null cells in the same glands, with the net result that c-MYC+;Pten-null cells outcompete Pten-null cells. Our results demonstrate the utility of accurate models to mimic the heterogeneous and incremental nature of human prostate carcinogenesis.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 101 108 101 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 506 513 506 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 811 814 811 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Tomlins1">[1]</xref>
###xml 880 883 880 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Gurel1">[2]</xref>
###xml 884 887 884 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-EllwoodYen1">[3]</xref>
###xml 894 898 894 898 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 972 975 960 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Steck1">[4]</xref>
###xml 976 979 964 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-McMenamin1">[8]</xref>
###xml 1331 1334 1319 1322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-EllwoodYen1">[3]</xref>
###xml 1335 1338 1323 1326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Zhang1">[9]</xref>
###xml 1351 1355 1339 1343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1401 1405 1389 1393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Wang1">[10]</xref>
###xml 1406 1410 1394 1398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Chen1">[13]</xref>
###xml 1415 1419 1403 1407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1537 1541 1525 1529 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kip1</sup>
###xml 1534 1541 1522 1529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p27<sup>Kip1</sup></italic>
###xml 1541 1545 1529 1533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-DiCristofano1">[14]</xref>
###xml 1546 1550 1534 1538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Kim1">[15]</xref>
###xml 1552 1557 1540 1545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trp53</italic>
###xml 1557 1561 1545 1549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Chen1">[13]</xref>
###xml 1566 1571 1554 1559 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fgf8b</italic>
###xml 1571 1575 1559 1563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Zhong1">[16]</xref>
###xml 782 787 <span type="species:ncbi:9606">human</span>
###xml 949 954 <span type="species:ncbi:9606">human</span>
###xml 1039 1044 <span type="species:ncbi:10090">mouse</span>
###xml 1264 1269 <span type="species:ncbi:10090">mouse</span>
###xml 1363 1367 <span type="species:ncbi:10090">mice</span>
Prevailing models of multistep carcinogenesis posit that oncogenic mutations arise in isolated cells in situ followed by clonal expansion. This implies that important competitive interactions occur between mutant and normal cells as well as between cells with distinct oncogenic mutations during tumorigenesis. A detailed understanding of these interactions will further efforts aimed at therapeutic targeting of neoplastic and preneoplastic lesions. However, these interactions have not been well studied in vivo due to a paucity of appropriate models. We report here our attempt to model these interactions in a new transgenic model of prostate cancer, focusing on the oncogene c-MYC and the tumor suppressor Pten (Phosphatase and tensin homolog), both of which are implicated in human prostate tumorigenesis [1]. c-MYC overexpression is a common early event in prostate cancer [2],[3] while PTEN is deleted/mutated in approximately30% of primary human prostate cancers [4]-[8]. Previous attempts at modeling c-MYC overexpression in the mouse prostate have used prostate-specific promoters that target transgene expression to a majority of the cells in the prostatic epithelium. Depending on the strength of the promoter used, this resulted in various grades of mouse prostatic intraepithelial neoplasia (mPIN) or adenocarcinoma [3],[9]. Similarly, Pten-mutant mice develop mPIN and prostate cancer [10]-[13] and Pten inactivation can cooperate with mutations in oncogenes and tumor suppressors in prostate tumorigenesis, including p27Kip1[14],[15], Trp53[13] and Fgf8b[16].
###end p 6
###begin p 7
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 79 83 79 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Chen1">[13]</xref>
###xml 84 88 84 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Nogueira1">[17]</xref>
###xml 89 93 89 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Kim2">[18]</xref>
###xml 243 247 243 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cip1</sup>
###xml 240 247 240 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p21<sup>cip1</sup></italic>
###xml 276 280 276 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PUMA</italic>
###xml 400 404 400 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Hoffman1">[19]</xref>
###xml 491 495 491 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Zindy1">[20]</xref>
###xml 566 570 566 570 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cip1</sup>
###xml 563 570 563 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p21<sup>Cip1</sup></italic>
###xml 570 574 570 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Seoane1">[21]</xref>
###xml 740 744 740 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Zheng1">[22]</xref>
###xml 715 721 <span type="species:ncbi:10090">murine</span>
Pten loss has been reported to activate the p53 pathway, leading to senescence [13],[17],[18]. Activation of p53 may lead to cell cycle arrest or apoptosis depending on the downstream target genes induced (i.e. cell cycle arrest genes e.g. p21cip1 versus apoptotic genes e.g. PUMA). There is potential cross-talk between the c-MYC and the p53 pathways at various levels depending on the cell context [19]. c-MYC activation can increase ARF expression, thereby stabilizing p53 protein levels [20], and c-MYC can repress expression of some p53 target genes such as p21Cip1[21]. In addition, Pten and p53 coordinately control c-Myc protein levels with the latter playing a critical role in maintaining the stemness of murine neural stem cells [22].
###end p 7
###begin p 8
###xml 103 107 103 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Fearon1">[23]</xref>
###xml 159 164 159 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-MYC</italic>
###xml 290 294 290 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 75 80 <span type="species:ncbi:9606">human</span>
###xml 135 140 <span type="species:ncbi:10090">mouse</span>
To model the sporadic genetic alterations that are thought to occur during human somatic tumorigenesis [23], we generated a transgenic mouse in which a latent c-MYC transgene can be focally activated in the prostatic epithelium by Cre expression. We have also deleted one or both copies of Pten in the prostate concurrently with focal c-MYC overexpression, in order to examine the interactions of cell populations with distinct mutations within the same gland.
###end p 8
###begin title 9
Results
###end title 9
###begin title 10
###xml 14 26 14 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC</italic>
###xml 27 31 <span type="species:ncbi:10090">mice</span>
Generation of PbCre4;Z-MYC mice with focal, prostate-specific c-MYC overexpression
###end title 10
###begin p 11
###xml 69 74 69 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Z-MYC</italic>
###xml 128 160 128 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CMV enhancer/beta actin promoter</italic>
###xml 186 194 186 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">beta-geo</italic>
###xml 213 218 213 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-MYC</italic>
###xml 229 233 229 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Roh1">[24]</xref>
###xml 235 244 235 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g001">Figure 1A</xref>
###xml 335 344 335 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g001">Figure 1A</xref>
###xml 410 415 410 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Z-MYC</italic>
###xml 424 430 424 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4</italic>
###xml 436 440 436 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Wu1">[25]</xref>
###xml 500 509 500 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g001">Figure 1A</xref>
###xml 520 532 520 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC</italic>
###xml 654 663 654 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g001">Figure 1C</xref>
###xml 765 797 765 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CMV enhancer/beta actin promoter</italic>
###xml 895 904 895 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g001">Figure 1B</xref>
###xml 75 79 <span type="species:ncbi:10090">mice</span>
###xml 128 131 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 416 420 <span type="species:ncbi:10090">mice</span>
###xml 431 435 <span type="species:ncbi:10090">mice</span>
###xml 533 537 <span type="species:ncbi:10090">mice</span>
###xml 765 768 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
To target focal c-MYC expression in the prostate epithelium, we used Z-MYC mice that carry a single copy transgene in which the CMV enhancer/beta actin promoter drives expression of the beta-geo gene and a latent c-MYC transgene [24] (Figure 1A). Staining for beta-galactosidase confirmed mosaic expression in the prostate epithelium (Figure 1A). To induce c-MYC expression focally in the prostate, we crossed Z-MYC mice to PbCre4 mice [25] which express Cre recombinase in the prostatic epithelium (Figure 1A). Bigenic PbCre4;Z-MYC mice expressed c-MYC focally in cytokeratin 8 (CK8) positive prostate luminal epithelial cells but not p63+ basal cells (Figure 1C). Furthermore, c-MYC expression is not abrogated in castrated animals indicating that the use of the CMV enhancer/beta actin promoter in our model has uncoupled prostate-specific expression from androgen-dependent gene regulation (Figure 1B).
###end p 11
###begin title 12
###xml 20 32 20 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC</italic>
###xml 33 38 <span type="species:ncbi:10090">mouse</span>
c-MYC expression in PbCre4;Z-MYC mouse prostate is mosaic and uncoupled from androgen regulation.
###end title 12
###begin p 13
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Z-MYC</italic>
###xml 411 416 399 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Z-MYC</italic>
###xml 475 484 463 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CMV/Actin</italic>
###xml 571 583 559 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC</italic>
###xml 734 746 722 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC</italic>
###xml 475 478 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 614 619 <span type="species:ncbi:10090">mouse</span>
###xml 747 752 <span type="species:ncbi:10090">mouse</span>
(A) LacZ stain depicts mosaic expression of transgene in Z-MYC prostate. Arrows indicate LacZ-positive cells. The frequency of transgene-expressing cells varied depending on glands and lobes, but quantitative analysis indicated that overall, LacZ-positive cells comprised approximately17% of the epithelial cells in any LacZ-positive gland (a) and (b). (c) shows schematic representation of Cre excision of the Z-MYC construct. c-MYC expression is activated and regulated by CMV/Actin promoter after Cre-excision. (B) Immunostaining verifies sporadic c-MYC expression in PbCre4;Z-MYC prostate epithelium of intact mouse (a) and 17 weeks after castration (b). (C) c-MYC colocalizes with cytokeratin 8 (CK8) (a) but not with p63 (b) in PbCre4;Z-MYC mouse prostates.
###end p 13
###begin title 14
Mild pathology due to focal c-MYC overexpression
###end title 14
###begin p 15
###xml 152 168 152 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g002">Figure 2A and 2B</xref>
###xml 235 267 235 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CMV enhancer/beta actin promoter</italic>
###xml 392 404 392 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC</italic>
###xml 564 573 552 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g003">Figure 3G</xref>
###xml 648 653 624 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Z-MYC</italic>
###xml 665 674 641 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g001">Figure 1A</xref>
###xml 761 770 725 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g003">Figure 3G</xref>
###xml 868 880 832 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC</italic>
###xml 1090 1102 1054 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g003">Figure 3A&#8211;3F</xref>
###xml 1104 1108 1068 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Slaughter1">[26]</xref>
###xml 235 238 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 405 409 <span type="species:ncbi:10090">mice</span>
###xml 449 453 <span type="species:ncbi:10090">mice</span>
###xml 881 885 <span type="species:ncbi:10090">mice</span>
###xml 988 993 <span type="species:ncbi:9606">human</span>
Focal c-MYC activation resulted in mild pathology, with most prostates showing normal histology or low grade mPIN (LGPIN) lesions up to 2 years of age (Figure 2A and 2B). This is unlikely to be due to low level c-MYC expression as the CMV enhancer/beta actin promoter is known to drive high level transgene expression. A closer examination of the c-MYC expression pattern in the prostates of PbCre4;Z-MYC mice with no pathology showed that in young mice, the frequency of c-MYC-positive cells was approximately18% of the epithelial cells in c-MYC-positive glands (Figure 3G), evocative of the frequency of LacZ-positive cells (approximately17%) in Z-MYC prostates (Figure 1A). By 1 year, the frequency of c-MYC positive cells has increased to approximately43% (Figure 3G). The lack of discernible histological abnormality in the prostates of a large fraction of older PbCre4;Z-MYC mice in the face of abundant c-MYC expression is reminiscent of the phenomenon of "field cancerization" in human tumorigenesis where incipient mutant cells occupy tissue fields without any apparent pathology (Figure 3A-3F) [26]. These histologically normal but mutant cells may serve as targets for transformation with additional genetic mutations.
###end p 15
###begin title 16
###xml 13 25 13 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC</italic>
###xml 39 49 39 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-MYC/Pten</italic>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
Pathology of PbCre4;Z-MYC and compound c-MYC/Pten mutant mice.
###end title 16
###begin p 17
###xml 256 268 256 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC</italic>
###xml 343 355 343 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC</italic>
###xml 389 392 389 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/+</sup>
###xml 378 392 378 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Pten<sup>f/+</sup></italic>
###xml 438 441 438 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/+</sup>
###xml 421 441 421 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/+</sup></italic>
###xml 559 561 559 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/</sup>
###xml 542 561 542 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/</sup></italic>
###xml 561 562 561 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 775 778 767 770 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/+</sup>
###xml 758 778 750 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/+</sup></italic>
###xml 140 144 <span type="species:ncbi:10090">mice</span>
(A) Hematoxylin and eosin (H&E)-stained prostate sections were analyzed and the summary of the pathological grading is shown. (N, number of mice analyzed). (B) Representative images of H&E-stained sections show benign glands in control (a), focal LGPIN in PbCre4;Z-MYC (boxed region in b and higher magnification in (c), focal HGPIN lesion in PbCre4;Z-MYC (d), benign glands in PbCre4;Ptenf/+ (e), focal HGPIN lesions in PbCre4;Z-MYC;Ptenf/+ (boxed region in f and higher magnification in g) and focal micro-invasive cancer lesion (arrow) in PbCre4;Z-MYC;Ptenf/+ (h). Scale bars: 100 microm in (a,b,e,f) and 50 microm in (c,d,g,h). (C) c-MYC and smooth muscle actin (SMA) staining. Arrows in (c) indicate focal areas of disruption of SMA (micro-invasion) in PbCre4;Z-MYC;Ptenf/+ prostate. Scale bar: 100 microm.
###end p 17
###begin title 18
###xml 100 112 100 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC</italic>
###xml 113 117 <span type="species:ncbi:10090">mice</span>
Time-dependent increase in c-MYC-expressing cells without discernible histopathology in a subset of PbCre4;Z-MYC mice.
###end title 18
###begin p 19
###xml 75 87 75 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC</italic>
###xml 442 443 442 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(A-C) H&E images demonstrate absence of histopathological abnormalities in PbCre4;Z-MYC prostates at various ages. (D-F) Adjacent sections subject to immunofluorescent staining for c-MYC demonstrate the numbers of c-MYC-overexpressing cells increase in a time-dependent manner. (G) The number of c-MYC-positive cells in any c-MYC-positive gland was quantitated based on the immunostaining shown in (D-F). N = 3-4 prostate samples per group. *p<0.05.
###end p 19
###begin title 20
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
Focal c-MYC expression cooperates with Pten heterozygosity
###end title 20
###begin p 21
###xml 98 102 98 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 180 183 180 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/+</sup>
###xml 163 183 163 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/+</sup></italic>
###xml 254 258 254 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 275 283 275 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g002">Figure 2</xref>
###xml 309 313 309 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Wang1">[10]</xref>
###xml 314 318 314 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Ma1">[11]</xref>
###xml 378 382 378 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 487 503 487 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g002">Figure 2A and 2B</xref>
###xml 564 567 552 555 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/+</sup>
###xml 547 567 535 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/+</sup></italic>
###xml 775 791 763 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g002">Figure 2B and 2C</xref>
###xml 862 866 850 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 922 925 910 913 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/+</sup>
###xml 905 925 893 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/+</sup></italic>
###xml 1092 1096 1080 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Huang1">[27]</xref>
###xml 1098 1106 1086 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g004">Figure 4</xref>
###xml 35 39 <span type="species:ncbi:10090">mice</span>
###xml 429 433 <span type="species:ncbi:10090">mice</span>
###xml 568 572 <span type="species:ncbi:10090">mice</span>
###xml 926 930 <span type="species:ncbi:10090">mice</span>
###xml 974 978 <span type="species:ncbi:10090">mice</span>
Next, we generated compound mutant mice with prostate-specific deletion of one or both alleles of Pten concurrently with focal activation of c-MYC. Examination of PbCre4;Z-MYC;Ptenf/+ prostates revealed clear cooperation between c-MYC overexpression and Pten heterozygosity (Figure 2). As reported previously [10],[11] and confirmed by us here, conditional deletion of a single Pten allele had little effect on the prostate with mice up to 50 weeks of age showing minimal abnormalities (Figure 2A and 2B). By approximately10 weeks of age however, PbCre4;Z-MYC;Ptenf/+ mice already have evidence of focal HGPIN lesions. Over time, these animals develop micro-invasive cancer as confirmed by the presence of areas with disruption in smooth muscle actin (SMA) immunoreactivity (Figure 2B and 2C). We used immunohistochemistry to examine the status of the wild type Pten allele in the HGPIN/cancer lesions in PbCre4;Z-MYC;Ptenf/+ mice. Consistently, all lesions examined (N = 8 mice) showed loss of Pten protein expression and phosphorylation of its downstream signaling components Akt and Foxo1 [27] (Figure 4).
###end p 21
###begin title 22
###xml 65 68 65 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/+</sup>
###xml 48 68 48 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/+</sup></italic>
###xml 69 74 <span type="species:ncbi:10090">mouse</span>
Focal loss of Pten expression in PIN lesions of PbCre4;Z-MYC;Ptenf/+ mouse prostate.
###end title 22
###begin p 23
In focal PIN lesion (arrows), Pten protein expression is lost and phosphorylation of Akt and Foxo1 increased.
###end p 23
###begin title 24
###xml 0 11 0 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-MYC+;Pten</italic>
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">null</italic>
c-MYC+;Pten-null cells outcompete Pten-null cells in the same glands
###end title 24
###begin p 25
###xml 132 144 132 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC</italic>
###xml 181 185 181 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 239 248 239 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g005">Figure 5A</xref>
###xml 289 292 289 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/f</sup>
###xml 278 292 278 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Pten<sup>f/f</sup></italic>
###xml 314 317 314 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/f</sup>
###xml 297 317 297 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/f</sup></italic>
###xml 469 472 469 472 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/f</sup>
###xml 452 472 452 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/f</sup></italic>
###xml 548 557 548 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC+;Pten</italic>
###xml 663 672 663 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g005">Figure 5B</xref>
###xml 689 700 689 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-MYC+;Pten</italic>
###xml 757 761 757 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1143 1152 1143 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g005">Figure 5C</xref>
###xml 1157 1166 1157 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000542.s001">Figure S1</xref>
###xml 1242 1246 1242 1246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1493 1502 1493 1502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g005">Figure 5C</xref>
###xml 1537 1548 1537 1548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-MYC+;Pten</italic>
###xml 1576 1580 1576 1580 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1671 1674 1671 1674 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/f</sup>
###xml 1654 1674 1654 1674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/f</sup></italic>
###xml 1890 1899 1890 1899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g005">Figure 5D</xref>
###xml 1765 1769 <span type="species:ncbi:10090">mice</span>
We analyzed proliferation by staining for phospho-histone H3 (pHH3), a mitotic marker. Proliferation was increased significantly in PbCre4;Z-MYC prostates relative to controls, and Pten heterozygosity synergistically increased it further (Figure 5A). The proliferation rates in PbCre4;Ptenf/f and PbCre4;Z-MYC;Ptenf/f were similarly elevated. However, the focal nature of c-MYC expression in our model means that analysis of total proliferation in the PbCre4;Z-MYC;Ptenf/f prostates may not be an accurate measure of the proliferation in foci of c-MYC+;Pten-null cells. To overcome this, we performed double staining for c-MYC and phospho-histone H3. As shown in Figure 5B, double mutant (c-MYC+;Pten-null) cells were more proliferative than single mutant (Pten-null) cells within the same prostate glands. Furthermore, double mutant cells are histologically distinct from adjacent single mutant cells. The double mutant cells are of higher pathological grade with larger nuclei, high nuclear:cytoplasmic ratios, hyperchromatic nuclei with prominent chromocenters, focal chromatin clearing and prominent single or sometimes multiple nucleoli (Figure 5C and Figure S1). In addition, apoptotic and mitotic figures are prominent. Single mutant (Pten-null) cells on the other hand showed low nuclear grade with comparatively small and uniform nuclei, abundant pale cytoplasm and low nuclear:cytoplasmic ratios. These cells also have inconspicuous nucleoli and the chromatin is comparatively fine (Figure 5C). These observations suggest that c-MYC+;Pten-null cells may out-compete Pten-null cells within the same prostate gland over time. Indeed, analysis of PbCre4;Z-MYC;Ptenf/f animals showed that at early ages, c-MYC expression was focal within glands, but in older mice, lesions show uniform c-MYC expression, suggesting clonal expansion of c-MYC-positive cells in a time-dependent manner (Figure 5D).
###end p 25
###begin title 26
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
c-MYC expression increases the proliferation and tumorigenicity of Pten-deficient cells.
###end title 26
###begin p 27
###xml 168 171 168 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/f</sup>
###xml 151 171 151 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/f</sup></italic>
###xml 280 283 280 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/f</sup>
###xml 263 283 263 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/f</sup></italic>
###xml 319 320 319 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 329 330 329 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 342 343 342 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 466 469 466 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/f</sup>
###xml 449 469 449 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/f</sup></italic>
###xml 614 625 610 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-MYC+;Pten</italic>
###xml 648 652 644 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 725 728 721 724 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/f</sup>
###xml 708 728 704 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/f</sup></italic>
###xml 302 306 <span type="species:ncbi:10090">mice</span>
###xml 470 475 <span type="species:ncbi:10090">mouse</span>
###xml 729 733 <span type="species:ncbi:10090">mice</span>
(A) Proliferation was determined by analysis of phospho-histone H3 staining. (B) Phospho-histone H3 index in c-MYC-positive or c-MYC-negative cells in PbCre4;Z-MYC;Ptenf/f prostates. Inset: double staining shows colocalization of phospho-histone H3 with c-MYC in PbCre4;Z-MYC;Ptenf/f prostate. N = 3-4 mice per group. *p<0.05, **p<0.005, ****p<0.01. (C) c-MYC staining identifies MYC-expressing cells next to MYC-negative cells in the same gland of PbCre4;Z-MYC;Ptenf/f mouse prostate. An adjacent H&E-stained section is also shown. Note distinct, higher grade pathology of c-MYC+ cells. Scale bar: 50 microm. (D) c-MYC+;Pten-null cells outcompete Pten-null cells. Prostates from 10-week-old and 28-week-old PbCre4;Z-MYC;Ptenf/f mice were stained for c-MYC and smooth muscle actin. At 10 weeks, c-MYC expression is focal; at 28 weeks, it is uniform. Arrows indicate discontinuity of smooth muscle actin (focal micro-invasion). Scale bar: 100 microm.
###end p 27
###begin title 28
Pten loss does not protect c-MYC overexpressing prostate cells from apoptosis
###end title 28
###begin p 29
###xml 92 95 92 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/+</sup>
###xml 81 95 81 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Pten<sup>f/+</sup></italic>
###xml 210 222 210 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC</italic>
###xml 263 272 263 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g006">Figure 6A</xref>
###xml 454 458 454 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Pelengaris1">[28]</xref>
###xml 459 463 459 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Murphy1">[29]</xref>
###xml 497 509 497 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC</italic>
###xml 595 599 595 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 709 718 709 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g006">Figure 6A</xref>
###xml 945 948 945 948 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/+</sup>
###xml 928 948 928 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/+</sup></italic>
###xml 1122 1131 1122 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g006">Figure 6B</xref>
###xml 949 953 <span type="species:ncbi:10090">mice</span>
Analysis of apoptosis by staining for activated Caspase 3 shows that control and PbCre4;Ptenf/+ prostates had low levels of apoptosis, consistent with their normal histology, while focal expression of c-MYC in PbCre4;Z-MYC prostates modestly increased apoptosis (Figure 6A). Although c-MYC overexpression is known to induce apoptosis in several tissues, this depends on many variables including the level of c-MYC overexpression and the "tissue context" [28],[29]. The levels of apoptosis seen in PbCre4;Z-MYC prostates are consistent with increased cell turnover due to enhanced proliferation. Pten-null prostates also had increased rates of apoptosis, and c-MYC overexpression further enhanced this effect (Figure 6A). These results were surprising as Pten loss is known to activate pro-survival pathways. Therefore, we sought to determine if apoptosis is increased in HGPIN/cancer cells that have lost Pten expression in our PbCre4;Z-MYC;Ptenf/+ mice. Double staining for Pten and activated Caspase 3 and quantitative analysis indicated higher rates of apoptosis in Pten-negative cells compared to Pten-positive cells (Figure 6B). Thus Pten loss does not protect prostate cells from apoptosis due to c-MYC overexpression.
###end p 29
###begin title 30
###xml 25 35 25 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-MYC/Pten</italic>
###xml 52 56 <span type="species:ncbi:10090">mice</span>
Analysis of apoptosis in c-MYC/Pten compound mutant mice.
###end title 30
###begin p 31
###xml 99 102 99 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/+</sup>
###xml 82 102 82 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/+</sup></italic>
###xml 295 296 295 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 305 306 305 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 317 318 317 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 333 334 333 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 278 282 <span type="species:ncbi:10090">mice</span>
(A) Apoptosis was analyzed by staining for activated Caspase 3. (B) Sections from PbCre4;Z-MYC;Ptenf/+ prostates were doubly stained for activated Caspase 3 and Pten, and the number of apoptotic cells was quantitated in Pten-positive and Pten-negative epithelial cells. N = 3-4 mice per group. *p<0.05, **p<0.005, ***p<0.001 and ****p<0.01.
###end p 31
###begin p 32
###xml 90 94 90 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 122 126 122 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Vivanco1">[30]</xref>
###xml 127 131 127 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Yang1">[31]</xref>
###xml 188 192 188 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 223 227 223 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 284 294 284 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000542.s002">Figure S2A</xref>
###xml 455 459 455 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Bode1">[32]</xref>
###xml 507 511 507 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 873 882 873 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000542.s002">Figure S2</xref>
###xml 610 615 <span type="species:ncbi:9606">human</span>
In addition to Akt, the c-Jun N-terminal kinase (Jnk) pathway is known to be activated in Pten-deficient cells and tumors [30],[31]. We confirmed that the Jnk pathway is activated in both Pten-null and c-MYC-overexpressing/Pten-null prostates by immunohistochemistry for phospho-Jnk (Figure S2A). Since Jnk is well known to have the ability to activate apoptosis, cell survival and proliferation depending on cellular signal stimuli and cellular contexts [32], we asked if increased Jnk activity sensitizes Pten-deficient cells to apoptosis. We used small hairpin RNA to stably downregulate PTEN in the benign human prostatic cell line RWPE1. However, treatment with the Jnk inhibitor (SP600125) led to an increase in apoptosis in PTEN knockdown cells in a dose-dependent manner, suggesting that PTEN loss-induced Jnk activity is anti-apoptotic, rather than pro-apoptotic (Figure S2).
###end p 32
###begin title 33
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
c-MYC shifts the p53 response in Pten-deficient prostate cells from senescence to apoptosis
###end title 33
###begin p 34
###xml 17 21 17 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 210 214 210 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Chen1">[13]</xref>
###xml 215 219 215 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Nogueira1">[17]</xref>
###xml 220 224 220 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Kim2">[18]</xref>
###xml 225 229 225 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Yu1">[33]</xref>
###xml 299 309 299 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-MYC/Pten</italic>
###xml 439 443 439 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cip1</sup>
###xml 456 460 456 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 477 486 477 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g007">Figure 7A</xref>
###xml 554 558 554 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 578 582 578 582 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cip1</sup>
###xml 603 612 603 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g007">Figure 7A</xref>
###xml 666 670 666 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cip1</sup>
###xml 682 686 682 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Seoane1">[21]</xref>
###xml 735 744 735 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g007">Figure 7B</xref>
###xml 764 768 764 768 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cip1</sup>
###xml 837 841 837 841 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cip1</sup>
###xml 854 863 854 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g007">Figure 7B</xref>
###xml 890 894 890 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 964 968 964 968 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cip1</sup>
###xml 1094 1097 1094 1097 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/f</sup>
###xml 1077 1097 1077 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/f</sup></italic>
###xml 1112 1117 1112 1117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ink4a</sup>
###xml 1287 1296 1287 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g007">Figure 7C</xref>
###xml 1304 1308 1304 1308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1341 1345 1341 1345 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cip1</sup>
###xml 1485 1489 1485 1489 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cip1</sup>
It is known that Pten loss can activate the p53 pathway in the prostate cells and activation of the p53 pathway could lead to either senescence or apoptosis depending on the particular p53 target genes induced [13],[17],[18],[33]. We therefore sought to examine activation of the p53 pathway in our c-MYC/Pten model and to determine whether concurrent c-MYC expression alters the p53 response. We observed induction of p53, its targets p21cip1 and PUMA in Pten-null prostates (Figure 7A). However, while p53 and PUMA were induced in c-MYC-overexpressing Pten-null prostates, p21cip1 expression was not (Figure 7A), consistent with the notion that c-MYC represses p21cip1 expression [21]. Similar results were obtained in RWPE-1 cells (Figure 7B). While p53 and p21cip1 were induced upon PTEN knockdown, c-MYC overexpression repressed p21cip1 expression (Figure 7B). We hypothesized that in Pten-deficient cells with activation of the p53 pathway, repression of p21cip1 by c-MYC may switch the senescent response to apoptosis. Indeed, using immunofluorescence, we found that in PbCre4;Z-MYC;Ptenf/f prostates, p16ink4a expression (a marker of senescence) is mainly localized to c-MYC-negative cells while apoptosis (activated Caspase 3) is found predominantly among c-MYC-positive cells (Figure 7C). Thus Pten-deficiency activates the p53/p21cip1 pathway but concurrent c-MYC overexpression shifts the output of the pathway from senescence to apoptosis at least partly by repressing p21cip1.
###end p 34
###begin title 35
###xml 32 42 32 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-MYC/Pten</italic>
c-MYC and p53 pathway status in c-MYC/Pten mutant prostate cells.
###end title 35
###begin p 36
###xml 564 567 564 567 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/f</sup>
###xml 547 567 547 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/f</sup></italic>
###xml 42 46 <span type="species:ncbi:9696">Puma</span>
###xml 71 75 <span type="species:ncbi:10090">mice</span>
(A) Immunohistochemistry for p53, p21 and Puma. Prostate sections from mice of the indicated genotypes were stained with the indicated antibodies and nuclei were counterstained with hematoxylin. Positive cells (brown) are indicated by red arrows. (B) Western blots show expression of the indicated proteins in RWPE-1 cells expressing c-MYC, PTEN knockdown, or control vectors (FM-1, pLKO.1). PTEN and phospho-Akt (pAkt) blots confirm efficiency of PTEN knockdown. (C) Double immunofluorescent stains for c-MYC/p16 and c-MYC/activated Caspase 3 in PbCre4;Z-MYC;Ptenf/f prostates. Scale bar: 100 microm. (D) Model of interactions between c-MYC and Pten with the p53 pathway in c-MYC-initiated prostate cancer. Focal c-MYC overexpression leads to LGPIN and facilitates loss of Pten leading to HGPIN/invasive cancer. Activation of the p53 pathway due to Pten loss could lead to senescence or apoptosis. c-MYC expression is proposed to shift this response towards apoptosis by repressing p21 expression.
###end p 36
###begin title 37
Discussion
###end title 37
###begin p 38
###xml 398 403 398 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Z-MYC</italic>
###xml 517 522 517 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Z-MYC</italic>
###xml 563 567 563 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 77 82 <span type="species:ncbi:10090">mouse</span>
###xml 523 528 <span type="species:ncbi:10090">mouse</span>
Human prostate carcinogenesis is focal, random, and incremental, but current mouse models do not faithfully recapitulate this. Consequently, the competitive/cooperative interactions that may occur between mutant and normal cells during the early stages of tumorigenesis have not been well studied. The model described here exploits the stochastic expression of a "Cre-activatable" c-MYC transgene (Z-MYC) to induce c-MYC expression in isolated cells surrounded by normal cells. As illustrated by our studies when the Z-MYC mouse is crossed with prostate-specific Pten deletion, the focal nature of c-MYC expression allows analysis of cell populations with different genetic alterations within the same prostate gland.
###end p 38
###begin p 39
###xml 140 163 140 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CMV enhancer/beta actin</italic>
###xml 561 565 561 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 945 949 945 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Slaughter1">[26]</xref>
###xml 951 955 951 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Almadori1">[34]</xref>
###xml 956 960 956 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Chandran1">[37]</xref>
###xml 1340 1344 1340 1344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Felsher1">[38]</xref>
###xml 1345 1349 1345 1349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Neiman1">[39]</xref>
###xml 140 143 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 221 225 <span type="species:ncbi:10090">mice</span>
###xml 282 286 <span type="species:ncbi:10090">mice</span>
Our studies have yielded several insights. First, focal expression of c-MYC in prostate luminal epithelial cells, even though driven by the CMV enhancer/beta actin promoter, results in remarkably mild pathology with many mice showing histologically normal prostates and a subset of mice demonstrating LGPIN lesions. These results imply a remarkable tolerance of luminal epithelial cells to c-MYC expression. We showed that the acquisition of additional genetic mutations is essential for the appearance of discernable pathology by the fact that introduction of Pten heterozygosity into these animals resulted in cooperativity, with the development of HGPIN/cancer lesions which in all cases were associated with loss of Pten protein expression from the wild type allele. These observations highlight an important point about c-MYC-expressing cells in histologically "normal" glands, as may occur in tumors and tissues with "field cancerization" [26], [34]-[37] in that the overexpression of c-MYC in histologically "normal" cells may facilitate the acquisition of secondary mutations. Although it remains to be established whether loss of Pten expression is due to genetic, epigenetic or post-transcriptional control, c-MYC expression may facilitate acquisition of secondary mutations by increasing cell turnover and/or genomic instability [38],[39].
###end p 39
###begin p 40
###xml 21 24 21 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/f</sup>
###xml 4 24 4 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/f</sup></italic>
###xml 203 207 203 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 238 249 238 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-MYC+;Pten</italic>
###xml 275 279 275 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 301 305 301 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 348 359 348 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-MYC+;Pten</italic>
###xml 460 464 460 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Suzuki1">[40]</xref>
###xml 646 650 646 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Hill1">[41]</xref>
###xml 720 724 720 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 818 822 818 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 832 836 832 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Wang1">[10]</xref>
###xml 837 841 837 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Ma1">[11]</xref>
###xml 842 846 842 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Kimura1">[42]</xref>
###xml 864 869 864 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 900 904 900 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 992 996 992 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Radziszewska1">[43]</xref>
###xml 1011 1015 1011 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1095 1099 1095 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Chen1">[13]</xref>
###xml 1100 1104 1100 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Kim2">[18]</xref>
###xml 1105 1109 1105 1109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Miyauchi1">[44]</xref>
###xml 1165 1169 1165 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Nogueira1">[17]</xref>
###xml 25 29 <span type="species:ncbi:10090">mice</span>
###xml 603 607 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 631 636 <span type="species:ncbi:10090">mouse</span>
###xml 686 690 <span type="species:ncbi:10090">mice</span>
Our PbCre4;Z-MYC;Ptenf/f mice allowed us to examine the behavior of prostate cells with distinct mutations in the same prostate. c-MYC expression clearly confers an additional proliferative advantage to Pten-null prostate cells, allowing c-MYC+;Pten-null cells to outcompete Pten-null cells. However, Pten deficiency did not alleviate apoptosis in c-MYC+;Pten-null cells. This may appear surprising in light of the well-known, pro-survival effect of Pten loss [40] and a report that Pten loss decreased the apoptosis engendered by the inactivation of retinoblastoma (pRb) family proteins by a truncated SV40 T large antigen in the mouse prostate [41]. Nevertheless, previous studies of mice with conditional deletion of Pten in the prostate and testicular germline cells have noted an increased rate of apoptosis upon Pten deletion [10],[11],[42] and Radziszewska et al recently showed that deleting Pten concurrently with c-MYC activation in pancreatic beta cells led to increased apoptosis [43]. Furthermore, Pten deficiency has been reported to activate the p53 pathway leading to senescence [13],[18],[44] as well as to sensitize cells to ROS-induced apoptosis [17].
###end p 40
###begin p 41
###xml 135 144 135 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000542-g007">Figure 7D</xref>
###xml 219 223 219 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 360 365 360 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trp53</italic>
###xml 425 429 425 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cip1</sup>
###xml 422 429 422 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p21<sup>cip1</sup></italic>
###xml 462 471 462 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PUMA, Bax</italic>
###xml 617 621 617 621 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cip1</sup>
###xml 614 621 614 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p21<sup>cip1</sup></italic>
Based on our studies and published reports, we propose the following model of cooperativity between c-MYC and Pten in prostate cancer (Figure 7D): Overexpression of c-MYC initiates tumorigenesis by facilitating loss of Pten. The latter leads to the activation of the p53 pathway, which can result in either senescence or apoptosis depending on the predominant Trp53 target genes induced (i.e. cell cycle arrest genes e.g. p21cip1 versus pro-apoptotic genes e.g. PUMA, Bax etc.). The expression of c-MYC drives cells down the apoptotic pathway as it selectively represses the cell cycle arrest-inducing target gene p21cip1.
###end p 41
###begin p 42
###xml 213 217 213 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 357 362 357 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-MYC</italic>
###xml 367 371 367 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 390 394 390 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 443 447 443 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 60 65 <span type="species:ncbi:10090">mouse</span>
###xml 130 135 <span type="species:ncbi:9606">human</span>
To summarize, we report a new Cre-dependent prostate cancer mouse model that reflects the focal, random and incremental nature of human prostate carcinogenesis. We show that focal c-MYC expression cooperates with Pten heterozygosity to promote tumor progression due to the selection of cells with loss of Pten expression. In addition, cells mutant for both c-MYC and Pten outcompete single Pten-mutant cells within the same prostates although Pten-deficiency sensitizes cells to apoptosis that is associated with activation of the p53 pathway and exacerbated by c-MYC expression. Our results highlight the utility of modeling focal oncogene activation to study the interactions between cell populations with different genetic alterations in tumorigenesis.
###end p 42
###begin title 43
Materials and Methods
###end title 43
###begin title 44
Animals
###end title 44
###begin p 45
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Z-MYC</italic>
###xml 7 13 7 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PBCre4</italic>
###xml 22 25 22 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/f</sup>
###xml 18 25 18 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten<sup>f/f</sup></italic>
###xml 51 55 51 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Roh1">[24]</xref>
###xml 56 60 56 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Wu1">[25]</xref>
###xml 61 65 61 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Groszer1">[45]</xref>
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Z-MYC</italic>
###xml 112 118 112 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4</italic>
###xml 173 185 173 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC</italic>
###xml 225 228 225 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/f</sup>
###xml 221 228 221 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten<sup>f/f</sup></italic>
###xml 344 347 344 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/+</sup>
###xml 333 347 333 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Pten<sup>f/+</sup></italic>
###xml 368 371 368 371 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/+</sup>
###xml 358 371 358 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Z-MYC;Pten<sup>f/+</sup></italic>
###xml 414 426 414 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC</italic>
###xml 439 442 439 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/f</sup>
###xml 428 442 428 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Pten<sup>f/f</sup></italic>
###xml 461 464 461 464 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/+</sup>
###xml 444 464 444 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/+</sup></italic>
###xml 486 489 486 489 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/f</sup>
###xml 469 489 469 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/f</sup></italic>
###xml 26 30 <span type="species:ncbi:10090">mice</span>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
###xml 119 123 <span type="species:ncbi:10090">mice</span>
###xml 125 127 <span type="species:ncbi:10090">B6</span>
###xml 229 233 <span type="species:ncbi:10090">mice</span>
###xml 235 237 <span type="species:ncbi:10090">B6</span>
###xml 314 318 <span type="species:ncbi:10090">mice</span>
Z-MYC, PBCre4 and Ptenf/f mice have been described [24],[25],[45]. Female Z-MYC mice (B6/129) were bred to male PbCre4 mice (B6) obtained from MMHCC, Frederick, to generate PbCre4;Z-MYC offspring and littermate controls. Ptenf/f mice (B6/129) were obtained from The Jackson Laboratory. To generate compound mutant mice, we generated PbCre4;Ptenf/+ males and Z-MYC;Ptenf/+ females which were further bred to obtain PbCre4;Z-MYC, PbCre4;Ptenf/f, PbCre4;Z-MYC;Ptenf/+ and PbCre4;Z-MYC;Ptenf/f offspring for experiments as well as their littermate controls. Animal care and experiments were carried out according to the protocols approved by the Institutional Animal Care and Use Committees at Vanderbilt University.
###end p 45
###begin title 46
LacZ stain
###end title 46
###begin p 47
###xml 105 109 105 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Roh1">[24]</xref>
Beta-galactosidase staining followed by counterstaining with nuclear fast red was performed as described [24].
###end p 47
###begin title 48
Histology and immunohistochemistry
###end title 48
###begin p 49
###xml 66 70 66 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Abdulkadir1">[46]</xref>
###xml 132 136 132 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-MentorMarcel1">[47]</xref>
###xml 195 199 195 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Abdulkadir1">[46]</xref>
###xml 1043 1045 1043 1045 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">st</sup>
###xml 1147 1149 1147 1149 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nd</sup>
###xml 1211 1213 1211 1213 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nd</sup>
###xml 333 339 <span type="species:ncbi:9986">rabbit</span>
###xml 390 396 <span type="species:ncbi:9986">rabbit</span>
###xml 433 439 <span type="species:ncbi:9986">rabbit</span>
###xml 485 491 <span type="species:ncbi:9986">rabbit</span>
###xml 524 530 <span type="species:ncbi:9986">rabbit</span>
###xml 575 581 <span type="species:ncbi:9986">rabbit</span>
###xml 636 641 <span type="species:ncbi:10090">mouse</span>
###xml 711 717 <span type="species:ncbi:9986">rabbit</span>
###xml 759 764 <span type="species:ncbi:10090">mouse</span>
###xml 811 816 <span type="species:ncbi:10090">mouse</span>
###xml 844 850 <span type="species:ncbi:9986">rabbit</span>
###xml 878 882 <span type="species:ncbi:9696">Puma</span>
###xml 884 890 <span type="species:ncbi:9986">rabbit</span>
###xml 946 952 <span type="species:ncbi:9986">rabbit</span>
Tissues were prepared for histopathological analysis as described [46], and slides were reviewed by IEA based on published criteria [47]. Immunohistochemical analyses were performed as described [46]. The following antibodies were used, in some cases with Tyramide Signal Amplification (TSA; Perkin Elmer): anti-activated Caspase 3 (rabbit, 1:500, Cell Signaling), anti-phospho-histone H3 (rabbit, 1:500, Upstate), anti-phospho-Akt (rabbit, 1:100, Cell Signaling), anti-phospho-Foxo1 (rabbit, 1:50, Santa Cruz), anti-c-MYC (rabbit, 1:15,000 with TSA, Santa Cruz), anti-Pten (rabbit, 1:200 with TSA, Cell Signaling), anti-cytokeratin 8 (mouse, 1:2000, Sigma), anti-p63 (PIN Cocktail, Biocare Medical), anti-p53 (rabbit, 1:5000 with TSA, Santa Cruz), anti-p21 (mouse, 1:50, Santa Cruz), anti-smooth muscle actin (mouse, 1:2000, Sigma), anti-p16 (rabbit, 1:1000, Santa Cruz), anti-Puma (rabbit, 1:200, Cell Signaling) and anti-phospho-Jnk antibody (rabbit, 1:100, Cell Signaling). For double immunofluorescenct stains, c-MYC or Pten detected by 1st primary antibodies were amplified by TSA system (green, Fluorescein). Alexa Fluor 594 (red)-labeled 2nd secondary antibodies (Molecular Probes) were used to detect 2nd primary antibodies (anti-cytokeratin 8, anti-p63, anti-smooth muscle actin, anti-phospho-histone H3, anti-p16 and anti-activated Caspase 3). Nuclear stain (DAPI) and sample mounting were performed using Vectashield mounting medium (Vector Laboratories).
###end p 49
###begin title 50
Proliferation and apoptosis assay
###end title 50
###begin p 51
###xml 192 196 <span type="species:ncbi:10090">mice</span>
At least 500 cells per sample were counted and quantitated after immunohistochemistry for phospho-Histone H3 and activated Caspase 3, respectively. N = 3-4 prostate samples from 9-15 week-old mice per group.
###end p 51
###begin title 52
Cell lines
###end title 52
###begin p 53
###xml 616 620 616 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Araki1">[48]</xref>
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 122 128 <span type="species:ncbi:9913">bovine</span>
###xml 450 476 <span type="species:ncbi:11276">vesicular stomatitis virus</span>
###xml 646 651 <span type="species:ncbi:9606">human</span>
RWPE-1, benign human prostate epithelial cell line (ATCC) was cultured in keratinocyte serum-free media supplemented with bovine pituitary extract and EGF (Invitrogen). We used lentiviral-mediated gene transfer to generate PTEN knockdown/c-MYC overexpressing cells. 293FT packaging cells were plated on 10 cm culture dishes and transfected with PTEN shRNA construct/pLKO.1 vector control (Sigma) or the c-MYC construct/FM-1 vector control along with vesicular stomatitis virus glycoprotein (VSVG) envelope plasmid and delta 8.9 packaging plasmid to produce lentivirus. The FM-1 vector was obtained from J. Milbrandt [48] and was used to clone in human c-MYC cDNA. Three days after transfection, medium containing viral particles was collected and added to RWPE-1 for infection with polybrene (8 microg/ml). 24 hours post infection, medium was changed and another 24 hours later puromycin (1 microg/ml) was added for selection of sh-Pten/pLKO.1 cells. YFP-positive c-MYC/FM-1 cells were sorted by flow cytometry.
###end p 53
###begin title 54
Western blot analyses
###end title 54
###begin p 55
###xml 34 38 34 38 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000542-Roh2">[49]</xref>
###xml 82 87 <span type="species:ncbi:10090">mouse</span>
###xml 132 138 <span type="species:ncbi:9986">rabbit</span>
###xml 181 187 <span type="species:ncbi:9986">rabbit</span>
###xml 226 231 <span type="species:ncbi:10090">mouse</span>
###xml 263 268 <span type="species:ncbi:10090">mouse</span>
###xml 300 305 <span type="species:ncbi:10090">mouse</span>
###xml 357 361 <span type="species:ncbi:9925">goat</span>
These were performed as described [49] using the following antibodies: anti-Pten (mouse, 1:1000, Cell signaling), anti-phospho-Akt (rabbit, 1:2000, Cell signaling), anti-total Akt (rabbit, 1:2000, Cell signaling), anti-c-MYC (mouse, 1:500, Santa Cruz), anti-p53 (mouse, 1:1000, Santa Cruz), anti-p21(mouse, 1:1000, Santa Cruz) and anti-beta-actin antibody (goat, 1:1000, Santa Cruz).
###end p 55
###begin title 56
Jnk inhibitor treatment and immunocytochemistry for activated Caspase 3
###end title 56
###begin p 57
Coverslips were placed on the 24-well plates and 300,000 control or Pten knockdown RWPE-1 cells were plated on the coverslips. Next day, cells were treated with Jnk inhibitor (SP600125) or vehicle (DMSO) at 0, 10 or 50 microM for one hour. Then cells were washed with phosphate buffered saline and supplement-free medium was added to induce apoptosis. After 48 hours, immunocytochemistry for activated Caspase 3 was performed and apoptosis was quantitated from triplicate data per group.
###end p 57
###begin title 58
Statistical analyses
###end title 58
###begin p 59
###xml 28 29 28 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 87 88 87 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
We compared groups by using t-test. Values are considered statistically significant at P<0.05. Quantitative variables are expressed as means+/-SD while categorical variables are expressed as numbers (%).
###end p 59
###begin title 60
Supporting Information
###end title 60
###begin p 61
###xml 29 32 29 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/f</sup>
###xml 18 32 18 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Pten<sup>f/f</sup></italic>
###xml 54 57 54 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/f</sup>
###xml 37 57 37 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/f</sup></italic>
###xml 101 104 101 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/f</sup>
###xml 84 104 84 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/f</sup></italic>
###xml 105 109 <span type="species:ncbi:10090">mice</span>
Histopathology of PbCre4;Ptenf/f and PbCre4;Z-MYC;Ptenf/f tumors at different ages. PbCre4;Z-MYC;Ptenf/f mice show higher grade lesions. Scale bars: 100 microm and 50 microm in insets: higher magnifications.
###end p 61
###begin p 62
(6.19 MB TIF)
###end p 62
###begin p 63
Click here for additional data file.
###end p 63
###begin p 64
###xml 117 120 117 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/f</sup>
###xml 106 120 106 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Pten<sup>f/f</sup></italic>
###xml 142 145 142 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f/f</sup>
###xml 125 145 125 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4;Z-MYC;Pten<sup>f/f</sup></italic>
Jnk is activated in Pten-deficient cells and is anti-apoptotic. (A) Phospho-Jnk expression is apparent in PbCre4;Ptenf/f and PbCre4;Z-MYC;Ptenf/f prostates (brown). (B) Apoptosis increases in Pten-knockdown RWPE-1 cells when treated with Jnk inhibitor (SP600125). (C) Western blots show that Pten knockdown is efficient in PTEN-shRNA-infected RWPE-1 cells. Immunofluorescence images represent increased apoptosis in PTEN-knockdown cells (red, activated Caspase 3). Nuclei were stained blue. *p<0.01.
###end p 64
###begin p 65
(6.79 MB TIF)
###end p 65
###begin p 66
Click here for additional data file.
###end p 66
###begin p 67
We thank Irina Doubinskaia for technical assistance.
###end p 67
###begin title 68
References
###end title 68
###begin article-title 69
Integrative biology of prostate cancer progression.
###end article-title 69
###begin article-title 70
###xml 61 66 <span type="species:ncbi:9606">human</span>
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis.
###end article-title 70
###begin article-title 71
###xml 11 17 <span type="species:ncbi:10090">murine</span>
###xml 65 70 <span type="species:ncbi:9606">human</span>
Myc-driven murine prostate cancer shares molecular features with human prostate tumors.
###end article-title 71
###begin article-title 72
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.
###end article-title 72
###begin article-title 73
###xml 62 67 <span type="species:ncbi:9606">human</span>
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.
###end article-title 73
###begin article-title 74
PTEN, a unique tumor suppressor gene.
###end article-title 74
###begin article-title 75
Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.
###end article-title 75
###begin article-title 76
###xml 23 38 <span type="species:ncbi:10090">transgenic mice</span>
Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein.
###end article-title 76
###begin article-title 77
###xml 34 40 <span type="species:ncbi:10090">murine</span>
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.
###end article-title 77
###begin article-title 78
###xml 47 52 <span type="species:ncbi:10090">mouse</span>
Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.
###end article-title 78
###begin article-title 79
###xml 48 53 <span type="species:ncbi:10090">mouse</span>
Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma.
###end article-title 79
###begin article-title 80
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.
###end article-title 80
###begin article-title 81
###xml 71 76 <span type="species:ncbi:10090">mouse</span>
Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse.
###end article-title 81
###begin article-title 82
###xml 55 60 <span type="species:ncbi:10090">mouse</span>
Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis.
###end article-title 82
###begin article-title 83
Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis.
###end article-title 83
###begin article-title 84
Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis.
###end article-title 84
###begin article-title 85
###xml 50 55 <span type="species:ncbi:9606">human</span>
Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.
###end article-title 85
###begin article-title 86
Apoptotic signaling by c-MYC.
###end article-title 86
###begin article-title 87
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization.
###end article-title 87
###begin article-title 88
Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage.
###end article-title 88
###begin article-title 89
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation.
###end article-title 89
###begin article-title 90
A genetic model for colorectal tumorigenesis.
###end article-title 90
###begin article-title 91
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
Transgenic mice for Cre-inducible overexpression of the oncogenes c-MYC and Pim-1 in multiple tissues.
###end article-title 91
###begin article-title 92
###xml 65 70 <span type="species:ncbi:10090">mouse</span>
Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation.
###end article-title 92
###begin article-title 93
Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin.
###end article-title 93
###begin article-title 94
Dynamic FoxO transcription factors.
###end article-title 94
###begin article-title 95
c-MYC: more than just a matter of life and death.
###end article-title 95
###begin article-title 96
Distinct thresholds govern Myc's biological output in vivo.
###end article-title 96
###begin article-title 97
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN.
###end article-title 97
###begin article-title 98
Bone morphogenetic protein 7 protects prostate cancer cells from stress-induced apoptosis via both Smad and c-Jun NH2-terminal kinase pathways.
###end article-title 98
###begin article-title 99
The functional contrariety of JNK.
###end article-title 99
###begin article-title 100
The transcriptional targets of p53 in apoptosis control.
###end article-title 100
###begin article-title 101
Multistep laryngeal carcinogenesis helps our understanding of the field cancerisation phenomenon: a review.
###end article-title 101
###begin article-title 102
A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications.
###end article-title 102
###begin article-title 103
Cancer initiation and progression: an unsimplifiable complexity.
###end article-title 103
###begin article-title 104
Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors.
###end article-title 104
###begin article-title 105
Transient excess of MYC activity can elicit genomic instability and tumorigenesis.
###end article-title 105
###begin article-title 106
Myc oncogene-induced genomic instability: DNA palindromes in bursal lymphomagenesis.
###end article-title 106
###begin article-title 107
Keratinocyte-specific Pten deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and tumor formation.
###end article-title 107
###begin article-title 108
Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model.
###end article-title 108
###begin article-title 109
Conditional loss of PTEN leads to testicular teratoma and enhances embryonic germ cell production.
###end article-title 109
###begin article-title 110
PTEN Deletion and Concomitant c-Myc Activation Do Not Lead to Tumor Formation in Pancreatic {beta} Cells.
###end article-title 110
###begin article-title 111
###xml 50 55 <span type="species:ncbi:9606">human</span>
Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway.
###end article-title 111
###begin article-title 112
Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo.
###end article-title 112
###begin article-title 113
###xml 50 54 <span type="species:ncbi:10090">mice</span>
Impaired prostate tumorigenesis in Egr1-deficient mice.
###end article-title 113
###begin article-title 114
###xml 97 112 <span type="species:ncbi:10090">transgenic mice</span>
Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP).
###end article-title 114
###begin article-title 115
Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration.
###end article-title 115
###begin article-title 116
Chromosomal instability induced by Pim-1 is passage-dependent and associated with dysregulation of cyclin B1.
###end article-title 116
###begin p 117
The authors have declared that no competing interests exist.
###end p 117
###begin p 118
This work was supported by NIH grants CA094858 and CA123484 (SAA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 118

